Medicinal Products

PARLODEL 10 mg

Generic Drug Therapeutic Class: Neurology-Psychiatry
active ingredients: Bromocriptine
laboratory: Meda Pharma

capsule
Box of 30
All forms

Indication

Parkinson disease

· First-line treatment in monotherapy.

· First-line treatment with levodopa (in this second case, to decrease the dose of each of the active products and to delay the onset of fluctuations in efficacy and abnormal movements).

· Association in the course of evolution of the disease in case of:

o decrease in the effect of levodopa;

o fluctuations in the therapeutic effect of dopa therapy and other phenomena appearing after several years of treatment with levodopa: dyskinesia, painful dystonia.

· Ineffectiveness from the start of dopa therapy.

The switch from levodopa to bromocriptine should always be done gradually, with reduced doses of levodopa (see section Dosage and method of administration ).

Dosage PARLODEL 10 mg Capsule Box of 30

The adaptation of the individual dosage will also be a function of tolerance.

The prescription of domperidone 3 days before the beginning of the treatment and during the progression makes it possible to initiate the treatment with a good acceptability (see under Undesirable effects ).

At the beginning of treatment, Parlodel tablets containing 2.5 mg of bromocriptine will be used.

The therapeutic scheme is as follows:

· ½ tablet the first day at the evening meal,

· 1 tablet on the 2nd day, then gradually increase in steps of one tablet every other day.

From 20 mg per day, Parlodel 5 mg then 10 mg capsules replace the tablets.

The average effective doses (to be divided into 3 daily doses) are:

· As monotherapy: 10 mg to 30 mg daily;

· In early combination with levodopa: 10 mg to 25 mg daily.

However, in some patients, higher doses may be exceptionally needed.

In patients after 65 years, the daily dose is between 5 and 15 mg (see section 4.4 ).

In combination with levodopa, Parlodel reduces daily doses of levodopa by 20 to 60%.

Against indications

· Hypersensitivity to bromocriptine or other ergot alkaloids.

· For long-term treatment: sign of cardiac valvulopathy detected during echocardiography performed before treatment.

· Pregnancy, postpartum or postpartum hypertension.

· Coronary insufficiency.

· Patients with severe psychiatric disorders (and / or psychiatric history) with vascular risk factors or peripheral arterial disease.

· Combination with anti- emetic neuroleptics (see section Interactions with other medicinal products and other forms of interaction ).

· Combination with phenylpropanolamine (see section Interactions with other medicinal products and other forms of interaction ).

Parlodel side effects

Adverse events are ranked in descending order of frequency, as follows: very common (≥ 1/10); frequent (≥ 1/100, <1/10); uncommon (≥ 1/1000, <1/100); rare (≥ 1 / 10, 000, <1/1000); very rare (<1 / 10, 000), including isolated cases

Psychiatric disorders

Uncommon: confusion *, psychomotor agitation *, hallucinations *

Rare: psychotic disorders

These psychiatric disorders can be observed more particularly at high doses and mainly in patients already showing signs of mental deterioration. These disorders require the reduction of the dosage, or even the cessation of treatment.

Cases of pathological gambling (compulsive gambling), hypersexuality and increased libido have been reported since marketing mainly at high dosages (see section 4.4 ).

Central nervous system disorders

Common: headache *, dizziness, slumber *

Uncommon: dyskinesia *

Rare: drowsiness,

Very rare: excessive daytime sleepiness, sudden onset of sleep

Cardiac disorders

Rare: constrictive pericarditis.

Very rare: cardiac valvulopathy (including regurgitation) and associated disorders (pericarditis and pericardial effusion).

Vascular disorders

Uncommon: hypotension, orthostatic hypotension * (leading exceptionally to collapse requiring reduction of dosage, or even discontinuation of treatment)

Very rare: reversible pallor of the extremities triggered by cold exposure, especially in patients with a history of Raynaud's syndrome

Respiratory disorders

Common: nasal congestion *

Rare: pleural effusion and pleuropulmonary fibrosis in long-term, high-dose, Parkinsonian patients (see section 4.4 ), pleurisy, dyspnoea

Gastrointestinal disorders

Common: nausea, constipation *, vomiting

Uncommon: Dry mouth *

Rare: abdominal pain, retroperitoneal fibrosis

Skin and subcutaneous tissue disorders

Uncommon: hair loss *, hives, eczema, maculopapular rash, erythematous rash.

Muscle, connective tissue and bone disorders

Uncommon: cramps in the legs *

General disorders and administration site conditions

Rare: peripheral edema

Very rare: syndrome resembling the neuroleptic malignant syndrome in case of abrupt cessation of treatment.

* Usually these unwanted effects (*) are dose-dependent and can be controlled by decreasing the dosage.

Popular Posts

Category Medicinal Products, Next Article